Shanghai Bao Pharmaceuticals_Providing professional financial news and data related to Shanghai Bao Pharmaceuticals, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

Shanghai Bao Pharmaceuticals(02659.HK): IND Application for Injection BJ044 Approved by NMPA

Tags：

Shanghai Bao Pharmaceuticals 02659.HK

2026-06-30

Finance
Shanghai INT Medical(01501.HK): Grant of 33,400 H-share Awards to Executive Director Liang Dongke
Finance
HK.AI CAPITAL(01140.HK): Non-executive Director Wang Qin Resigns, Lin Jing Appointed as Chairman and Authorised Representative
Finance
Modern Dairy (01117.HK): Takeover Offer for China Shengmu, Offer Period Ends on July 21
Finance
Luxshare Precision (02475.HK): Launches Hong Kong IPO with Maximum Offer Price of HK$63.28 per Share
Finance
Ascletis Pharma(01672.HK): Proposed Share Repurchase of Up to HK$300 Million
Finance
BOC Aviation (02588.HK): Purchase Three Airbus A350-1000 Aircraft from Qatar Airways and Enter into Sale-and-Leaseback Arrangement
Finance
Insilico Medicine (03696.HK): Two Core Senior Executives Voluntarily Extend Lock-up Period to June 2027
Finance
Zhongguancun Science-Tech Leasing (01601.HK): Invests RMB 92 Million to Purchase 40 Autonomous Mining Trucks for Operating Leasing Business
Finance
CM Energy Tech(00206.HK): Changes to Several Non-executive Directors
Finance
Baijin Life Science(01466.HK): Profit Warning, Expected Annual Loss Widens to No More Than HK$43 Million

Scan QR Code

Download App